Piper Sandler Reiterates Axsome's Price Target Maintains Overweight Rating

Summary

Piper Sandler reaffirmed the target price of $148 for Axsome Therapeutics Inc. (NASDAQ: AXSM), despite the FDA issuing a refusal to file notification for its new drug application for AXS-14. Analysts maintained an ‘overweight’ rating, noting that the setback is unlikely to significantly affect Axsome’s stock price. They believe the FDA’s request for additional studies could be advantageous due to the lack of new approvals in the fibromyalgia field. Despite acknowledging Axsome’s potential, analysts suggested that certain AI stocks might offer better investment opportunities.insidermonkey

Impact Analysis

First-Order Effects: The direct impact on Axsome Therapeutics involves maintaining investor confidence despite the regulatory hurdle, as evidenced by Piper Sandler’s reaffirmation of the stock’s target price and ‘overweight’ rating. The requirement for additional studies by the FDA could position Axsome advantageously in the long term, as the fibromyalgia treatment space lacks new approvals.insidermonkey Second-Order Effects: The FDA’s decision might influence peer companies in the fibromyalgia treatment domain, potentially increasing competition if Axsome successfully meets the FDA’s requirements and gains approval in the future. Investment Opportunities: Investors maintaining or initiating positions in Axsome should consider the potential delay in revenue from AXS-14 but also weigh the potential long-term advantages if the drug eventually secures approval. Additionally, analysts suggest exploring investment in AI stocks, which may currently offer better opportunities.insidermonkey